Fierce Biotech’s top 10 data readouts in 2022
To view this email as a web page, click here

Today's Rundown

Featured Story

Novartis brings on first TIGIT drug in massive billion-dollar biobucks deal with BeiGene

After watching Gilead and Roche dive deeper into TIGIT immunotherapies, Novartis is heading straight for the senior class. The Swiss pharma is getting in on the game via a blockbuster deal with BeiGene, which could ultimately net $1 billion for a late-stage asset.

read more

Top Stories

This is just the Spark: Roche's new gene therapy manufacturing center leaves space for growth

Since coming under the Roche banner in 2019, Spark Therapeutics has been working towards a massive expansion of its manufacturing capacity. Those efforts came to fruition Friday, and the companies intend to leave a few rooms open in the new $575 million facility for future growth.

read more

Fierce Biotech’s top 10 data readouts in 2022

There are a number of potential blockbuster drugs on the list, but it’s not all about revenue potential. Many of the compounds are high-risk, high-reward candidates trying to push the boundaries of drug treatment.

read more

Roche adds to Genentech's ophthalmology program with $720M in biobucks for Lineage Cell Therapeutics' asset

Roche’s Genentech has signed what could be a $720 million deal for Lineage Cell Therapeutics’ cell therapy for a range of eye disorders. Lineage is developing a retinal pigment epithelium cell therapy in dry age-related macular degeneration with geographic atrophy.

read more

Novartis suffers shock setback as Xolair successor fails phase 3

Novartis’ attempt to establish ligelizumab as the successor to its blockbuster Xolair has hit a roadblock. The new molecule failed to better the old stager in a phase 3 clinical trial, leaving Novartis uncertain of its next steps for the program.

read more

Forbion arms biotech to stop sudden cardiac death, leading $35M round to fund phase 2 trial of Armgo's pipeline-in-a-product

Armgo Pharma is returning to its roots to deliver clinical proof of concept for its pipeline-in-a-product. After shifting focus from abnormal heart rhythm to neuromuscular disorders, Armgo is now returning to arrhythmias for its push into phase 2—and has armed itself with $35 million from Forbion and other VCs to go after the indication. 

read more

A colon growth hormone could pave way for treating aging-related disorders

Researchers say they have found a growth hormone in the colon that helps damage DNA, which aides in the aging process. The finding could lead to new therapeutic approaches to aging-associated disorders like cancer. 

read more

Biogen halves Aduhelm's price and plots cost cuts as Medicare decision on controversial Alzheimer's drug nears

As the Centers for Medicare & Medicaid Services is expected to make a coverage decision on Biogen’s controversial Alzheimer’s drug Aduhelm, the biotech is making an unexpected goodwill gesture—and an expected restructuring—as it faces pressure from all fronts.

read more

Mental health startup Cerebral teams with Alto Neuroscience to bring 'precision psychiatry' to patients' homes

Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes. Through the collaboration, Cerebral is able to offer its network of members the opportunity to participate in at-home clinical research utilizing Alto’s biomarker platform and targeted drug candidates.

read more

FDA clears muscle stimulator for increasing blood flow in the lower legs

The FDA greenlighted U.K.-based Sky Medical's wearable electrical muscle stimulator to help stave off some of the symptoms of chronically blocked vessels such as varicose veins and blood pooling in the legs. The geko device, about the size of a wristwatch, stimulates a central nerve located at the top of the shin to increase circulation.

read more

Bluebird bio hits FDA clinical hold—again—for gene therapy in sickle cell disease

Bluebird bio simply can’t catch a break. Just half a year after coming off an FDA clinical hold, development of the biotech’s blood disease gene therapy LentiGlobin has once again been halted, this time in sickle cell disease patients under the age of 18.

read more

Resources

Research: How Buffer Prep Services Alleviate Sudden Spikes in Campaign Volume

Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific

Whitepaper: Tailored, Dedicated Support Expedites COVID-19 Vaccine Trial

Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference.

Whitepaper: Patients Want Choice Offered through Hybrid Clinical Trials

New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer.

Whitepaper: Healthcare Technical Due Diligence: Assessing a New Cancer Treatment

A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more.

Whitepaper: Demand Planning for New Drug/Device Combination

Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study.

Whitepaper: QC for ex vivo manipulated cell lines and tissues

A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants.

Whitepaper: Modernizing Key Clinical Trial Processes with Artificial Intelligence

This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively.

Whitepaper: Medable was able to cut costs in multiple clinical trials by over US$25,000,000

Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper.

Webinar: Using Next Best to Elevate your Omnichannel Marketing Strategy

Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making.

Webinar: The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Whitepaper: Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

 

Events